Share

    


Home / Search Results

Search Results

Search Publications

Search Again?

Filter By Content Type

Filter By Topic

2024 Corporate Membership Program 1 Corporate Member Levels: Premier Platinum Gold Annual Fee per State Society $20,000 Limited to three (3) companies per State Society first come, first served $14,000 $10,000 Year-Round Visibility Digital ad on state society website Resources page 728 x 90 and 300 x 250 pixels available • One (1) dedicated stand-alone e-blast to …
This is the second post of a three-part series on Modern Healthcare’s Social Determinants of Health Symposium.
2024 Corporate Membership Program 1 Corporate Member Levels: Premier Platinum Gold Annual Fee per State Society $20,000 Limited to three (3) companies per State Society first come, first served $14,000 $10,000 Year-Round Visibility Digital ad on state society website Resources page 728 x 90 and 300 x 250 pixels available • One (1) dedicated stand-alone e-blast to …
2024 Corporate Membership Program 1 2024 WAHO Corporate Membership Program Corporate Member Levels: Premier Platinum Gold Annual Fee per State Society $24,000 Limited to three (3) companies per State Society first come, first served $16,000 $10,000 Year-Round Visibility Digital ad on state society website Resources page 728 x 90 and 300 x 250 pixels available • One …
2024 Corporate Membership Program 1 Corporate Member Levels: Premier Platinum Gold Annual Fee per State Society $20,000 Limited to three (3) companies per State Society first come, first served $14,000 $10,000 Year-Round Visibility Digital ad on state society website Resources page 728 x 90 and 300 x 250 pixels available • One (1) dedicated stand-alone e-blast to …
10 Steps to Success: Integrating Oral Oncolytics into Chronic Lymphocytic Leukemia (CLL) Practice EFFECTIVE PRACTICE GUIDE Oral Oncolytic Clinical Workflow for Treatment of Patients with Chronic Lymphocytic Leukemia OTC = over the counter, Rx=prescription, ACCC FAN = Association of Community Cancer Centers Financial Advocacy Network), EMR=Electronic Medical Record Clinical …
January 11, 2024
Join us in the New Year for an interactive evening and networking dinner in New Orleans. Explore the forefront of medical advancements in oncology and hematology with engaging talks by talented fellows. Topics will range from the latest breakthroughs in oncology to innovative approaches in medical education. RSVP by Friday, January 5, 2024, to Amanda Impellizzeri at aimpellizzeri@accc-cancer.org. Or …
TxSCO ONCOLOGY DRUG NEWSLETTER J A N U A R Y 2 0 2 4 This content is being shared with permission from MJH Life Sciences. All content of Targeted Oncology is independently created and owned by MJH Life Sciences. FDA APPROVALS Pirtobrutinib (Jaypirca) The FDA has approved pirtobrutinib (Jaypirca) in relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma …
TACOS ONCOLOGY DRUG NEWSLETTER J A N U A R Y 2 0 2 4 This content is being shared with permission from MJH Life Sciences. All content of Targeted Oncology is independently created and owned by MJH Life Sciences. FDA APPROVALS Pirtobrutinib (Jaypirca) The FDA has approved pirtobrutinib (Jaypirca) in relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma …
This is the second blog post is on the NCCN Patient Advocacy Summit: Navigating the Care Continuum from Screening Through Survivorship.
SCOS ONCOLOGY DRUG NEWSLETTER J A N U A R Y 2 0 2 4 This content is being shared with permission from MJH Life Sciences. All content of Targeted Oncology is independently created and owned by MJH Life Sciences. FDA APPROVALS Pirtobrutinib (Jaypirca) The FDA has approved pirtobrutinib (Jaypirca) in relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma …
January 11, 2024 TxSCO Update Overview: Notable Updates 2 Federal • Notable 2024 Congressional retirements • 2024 federal healthcare priorities • Recap: House passes Lower Costs, More Transparency Act • CY 2024 Physician Fee Schedule responses • Stark/in-office dispensing update • Medicaid redetermination forecasts State • Primary Season • TDI Rulemaking …
NCOA ONCOLOGY DRUG NEWSLETTER J A N U A R Y 2 0 2 4 This content is being shared with permission from MJH Life Sciences. All content of Targeted Oncology is independently created and owned by MJH Life Sciences. FDA APPROVALS Pirtobrutinib (Jaypirca) The FDA has approved pirtobrutinib (Jaypirca) in relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma …
Sutter Health details innovative programs designed to drive health equity at the most recent Modern Healthcare Social Determinants of Health Symposium.
ASSOCIATION OF COMMUNITY CANCER CENTERS 1 Preparing for Your Poster Session at the ACCC 50th Annual Meeting & Cancer Center Business Summit Creating Your Poster As you develop your poster, determine which aspects of your research project are most interesting and important and consider how you can communicate that information visually. Posters are most effective when they mix …
CME/MOC/AAPA PRESENTER Melissa L. Johnson, MD Amplifying the ADC Advantage How to Fulfill the Potential of Antibody–Drug Conjugates as the Next Frontier in Precision Lung Cancer Care Activity Description Mounting evidence continues to elucidate the clinical potential of antibody–drug conjugates (ADCs) in the treatment of patients with lung cancer. ADCs are now transitioning from research …
Join us for an Official Best of San Antonio Breast Cancer Symposium® hosted in collaboration with Wisconsin Association of Hematology and Oncology (WAHO), Medical College of Wisconsin, and the University of Wisconsin Carbone Cancer Center on February 3, 2024, at the Pfister Hotel in Milwaukee. Engage in interactive sessions facilitated by the nation’s top breast cancer experts, as they unveil …
CME/MOC/AAPA PRESENTER Melissa L. Johnson, MD Amplifying the ADC Advantage How to Fulfill the Potential of Antibody–Drug Conjugates as the Next Frontier in Precision Lung Cancer Care Activity Description Mounting evidence continues to elucidate the clinical potential of antibody–drug conjugates (ADCs) in the treatment of patients with lung cancer. ADCs are now transitioning from research …
10 Steps to Success: Integrating Oral Oncolytics into Chronic Lymphocytic Leukemia (CLL) Practice EFFECTIVE PRACTICE GUIDE Oral Oncolytic Clinical Workflow for Treatment of Patients with Chronic Lymphocytic Leukemia OTC = over the counter, Rx=prescription, ACCC FAN = Association of Community Cancer Centers Financial Advocacy Network), EMR=Electronic Medical Record Clinical …